Comparative analysis of human microglial models for studies of HIV replication and pathogenesis.


Journal

Retrovirology
ISSN: 1742-4690
Titre abrégé: Retrovirology
Pays: England
ID NLM: 101216893

Informations de publication

Date de publication:
19 11 2020
Historique:
received: 13 07 2020
accepted: 09 11 2020
entrez: 20 11 2020
pubmed: 21 11 2020
medline: 25 6 2021
Statut: epublish

Résumé

HIV associated neurocognitive disorders cause significant morbidity and mortality despite the advent of highly active antiretroviral therapy. A deeper understanding of fundamental mechanisms underlying HIV infection and pathogenesis in the central nervous system is warranted. Microglia are resident myeloid cells of the brain that are readily infected by HIV and may constitute a CNS reservoir. We evaluated two microglial model cell lines (C20, HMC3) and two sources of primary cell-derived microglia (monocyte-derived microglia [MMG] and induced pluripotent stem cell-derived microglia [iPSC-MG]) as potential model systems for studying HIV-microglia interactions. All four microglial model cells expressed typical myeloid markers with the exception of low or absent CD45 and CD11b expression by C20 and HMC3, and all four expressed the microglia-specific markers P2RY12 and TMEM119. Marked differences were observed upon gene expression profiling, however, indicating that MMG and iPSC-MG cluster closely together with primary human microglial cells, while C20 and HMC3 were similar to each other but very different from primary microglia. Expression of HIV-relevant genes also revealed important differences, with iPSC-MG and MMG expressing relevant genes at levels more closely resembling primary microglia. iPSC-MG and MMG were readily infected with R5-tropic HIV, while C20 and HMC3 lack CD4 and require pseudotyping for infection. Despite many similarities, HIV replication dynamics and HIV-1 particle capture by Siglec-1 differed markedly between the MMG and iPSC-MG. MMG and iPSC-MG appear to be viable microglial models that are susceptible to HIV infection and bear more similarities to authentic microglia than two transformed microglia cell lines. The observed differences in HIV replication and particle capture between MMG and iPSC-MG warrant further study.

Sections du résumé

BACKGROUND
HIV associated neurocognitive disorders cause significant morbidity and mortality despite the advent of highly active antiretroviral therapy. A deeper understanding of fundamental mechanisms underlying HIV infection and pathogenesis in the central nervous system is warranted. Microglia are resident myeloid cells of the brain that are readily infected by HIV and may constitute a CNS reservoir. We evaluated two microglial model cell lines (C20, HMC3) and two sources of primary cell-derived microglia (monocyte-derived microglia [MMG] and induced pluripotent stem cell-derived microglia [iPSC-MG]) as potential model systems for studying HIV-microglia interactions.
RESULTS
All four microglial model cells expressed typical myeloid markers with the exception of low or absent CD45 and CD11b expression by C20 and HMC3, and all four expressed the microglia-specific markers P2RY12 and TMEM119. Marked differences were observed upon gene expression profiling, however, indicating that MMG and iPSC-MG cluster closely together with primary human microglial cells, while C20 and HMC3 were similar to each other but very different from primary microglia. Expression of HIV-relevant genes also revealed important differences, with iPSC-MG and MMG expressing relevant genes at levels more closely resembling primary microglia. iPSC-MG and MMG were readily infected with R5-tropic HIV, while C20 and HMC3 lack CD4 and require pseudotyping for infection. Despite many similarities, HIV replication dynamics and HIV-1 particle capture by Siglec-1 differed markedly between the MMG and iPSC-MG.
CONCLUSIONS
MMG and iPSC-MG appear to be viable microglial models that are susceptible to HIV infection and bear more similarities to authentic microglia than two transformed microglia cell lines. The observed differences in HIV replication and particle capture between MMG and iPSC-MG warrant further study.

Identifiants

pubmed: 33213476
doi: 10.1186/s12977-020-00544-y
pii: 10.1186/s12977-020-00544-y
pmc: PMC7678224
doi:

Substances chimiques

Biomarkers 0

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA051895
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS107031
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150475
Pays : United States
Organisme : NIH HHS
ID : R21NS107031
Pays : United States
Organisme : NIH HHS
ID : R01 AI150475
Pays : United States

Références

Immunol Rev. 2013 Jul;254(1):102-13
pubmed: 23772617
AIDS. 2019 Dec 1;33 Suppl 2:S181-S188
pubmed: 31789817
J Neurovirol. 2010 Feb;16(1):76-82
pubmed: 20053142
Stem Cell Reports. 2017 Jun 6;8(6):1516-1524
pubmed: 28528700
Alzheimers Res Ther. 2017 Jun 13;9(1):42
pubmed: 28610595
Science. 2017 Jun 23;356(6344):
pubmed: 28546318
Eur J Neurosci. 2004 Nov;20(10):2617-28
pubmed: 15548205
J Neurovirol. 2017 Feb;23(1):33-46
pubmed: 27538994
Nat Neurosci. 2017 May;20(5):753-759
pubmed: 28253233
Glia. 2015 Mar;63(3):441-51
pubmed: 25331637
JAMA. 1986 Nov 7;256(17):2360-4
pubmed: 3639953
Cell Host Microbe. 2012 Sep 13;12(3):360-72
pubmed: 22980332
Prog Neurobiol. 2019 Aug;179:101614
pubmed: 31075285
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Nat Rev Neurosci. 2018 Aug;19(8):445-452
pubmed: 29977068
Genome Biol. 2014;15(12):550
pubmed: 25516281
Development. 2015 Jan 1;142(1):13-6
pubmed: 25516965
J Virol. 2010 Mar;84(5):2395-407
pubmed: 20015984
Lancet Neurol. 2014 Nov;13(11):1139-1151
pubmed: 25316020
Trends Microbiol. 2013 Aug;21(8):405-12
pubmed: 23735804
PLoS Pathog. 2017 Jan 27;13(1):e1006181
pubmed: 28129379
Cell Rep. 2017 Jan 10;18(2):391-405
pubmed: 28076784
J Neurovirol. 2018 Dec;24(6):665-669
pubmed: 30397827
Front Immunol. 2019 Jun 04;10:1170
pubmed: 31214167
J Virol. 1996 Nov;70(11):7654-62
pubmed: 8892885
Sci Transl Med. 2017 Dec 20;9(421):
pubmed: 29263232
Clin Infect Dis. 2019 Sep 27;69(8):1345-1352
pubmed: 30561541
Mol Neurodegener. 2018 Dec 22;13(1):67
pubmed: 30577865
Cell Stem Cell. 2019 May 2;24(5):829
pubmed: 31051135
Neuron. 2017 Apr 19;94(2):278-293.e9
pubmed: 28426964
AIDS. 2010 Jun 1;24(9):1243-50
pubmed: 19996937
Cell Host Microbe. 2007 Aug 16;2(2):85-95
pubmed: 18005723
Pathobiology. 1991;59(4):214-8
pubmed: 1883516
J Neurosci Methods. 2012 Jul 30;209(1):79-89
pubmed: 22659341
Methods Mol Biol. 2019;2034:3-11
pubmed: 31392673
J Neurovirol. 2012 Jun;18(3):191-9
pubmed: 22528480
Glia. 2002 Nov;40(2):240-51
pubmed: 12379911
Traffic. 2002 Oct;3(10):718-29
pubmed: 12230470
Nucleic Acids Res. 2019 May 7;47(8):e47
pubmed: 30783653
PLoS Pathog. 2019 Dec 30;15(12):e1008249
pubmed: 31887215
PLoS Biol. 2012;10(12):e1001448
pubmed: 23271952
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
Neurosci Lett. 1995 Aug 4;195(2):105-8
pubmed: 7478261
Rev Neurol (Paris). 1998 Dec;154(12):816-29
pubmed: 9932303
J Neuroinflammation. 2018 Sep 10;15(1):259
pubmed: 30200996
Front Immunol. 2015 May 26;6:249
pubmed: 26074918
J Neurosci. 2003 Feb 15;23(4):1198-205
pubmed: 12598608
Immunology. 2020 Jul;160(3):269-279
pubmed: 32053234
Retrovirology. 2015 May 07;12:37
pubmed: 25947229
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Front Immunol. 2013 Aug 14;4:236
pubmed: 23966995
Prog Neurobiol. 2019 Jul;178:101612
pubmed: 30954517
J Neurovirol. 2017 Feb;23(1):47-66
pubmed: 27873219
PLoS One. 2012;7(5):e35297
pubmed: 22567100
Virol J. 2020 Mar 6;17(1):31
pubmed: 32143686
Hum Pathol. 1991 Jul;22(7):700-10
pubmed: 2071114
Nat Med. 2016 Nov;22(11):1358-1367
pubmed: 27668937
Glia. 2017 Feb;65(2):375-387
pubmed: 27862351
Nat Commun. 2018 Oct 9;9(1):4167
pubmed: 30301888
Front Cell Neurosci. 2013 Mar 18;7:26
pubmed: 23507975
Exp Mol Pathol. 2019 Jun;108:64-72
pubmed: 30922769
Glia. 2006 Aug 15;54(3):183-92
pubmed: 16807899
Front Cell Infect Microbiol. 2019 Oct 24;9:362
pubmed: 31709195
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46
pubmed: 26884166
Brain Res. 2019 Dec 1;1724:146458
pubmed: 31521639
Clin Neuropathol. 1993 Nov-Dec;12(6):315-24
pubmed: 8287624
J Virol. 1991 Feb;65(2):736-42
pubmed: 1702842
PLoS Pathog. 2011 Oct;7(10):e1002286
pubmed: 22007152
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
J Virol. 2014 Aug;88(16):8813-25
pubmed: 24872578
J Infect Dis. 2008 May 15;197 Suppl 3:S294-306
pubmed: 18447615
Sci Rep. 2014 May 14;4:4957
pubmed: 24825127
Brain Pathol. 2002 Oct;12(4):442-55
pubmed: 12408230
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
Nat Neurosci. 2011 Sep 27;14(10):1227-35
pubmed: 21952260
mBio. 2017 Aug 15;8(4):
pubmed: 28811349
Stem Cell Reports. 2017 Jun 6;8(6):1727-1742
pubmed: 28591653
Stem Cell Reports. 2020 May 12;14(5):991
pubmed: 32402270

Auteurs

Mohammad A Rai (MA)

Division of Infectious Diseases, Cincinnati Children's Hospital, 3333 Burnet Avenue, MLC 7017, Cincinnati, OH, 45229, USA.
Division of Infectious Diseases, Department of Medicine, University of Cincinnati School of Medicine, Cincinnati, OH, USA.

Jason Hammonds (J)

Division of Infectious Diseases, Cincinnati Children's Hospital, 3333 Burnet Avenue, MLC 7017, Cincinnati, OH, 45229, USA.
Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH, USA.

Mario Pujato (M)

Division of Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, USA.
Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH, USA.

Christopher Mayhew (C)

Pluripotent Stem Cell Core Facility, Cincinnati Children's Hospital, Cincinnati, OH, USA.

Krishna Roskin (K)

Division of Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, USA.
Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH, USA.

Paul Spearman (P)

Division of Infectious Diseases, Cincinnati Children's Hospital, 3333 Burnet Avenue, MLC 7017, Cincinnati, OH, 45229, USA. paul.spearman@cchmc.org.
Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH, USA. paul.spearman@cchmc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH